Contact Information: Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs Formally Terminates Boston Stock Exchange Listing
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - May 15, 2009) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) (the
"Company") today announced that in conjunction with the termination of the
NASDAQ OMX BX (formerly known as the Boston Stock Exchange) listing
program, the Company will take steps to formally delist its common stock
from that exchange. Specifically, the Company will file a Form 25 with the
Securities and Exchange Commission in ten days effectuating this action.
The Company's common stock ceased to be listed on the former Boston Stock
Exchange in September 2007, and this action formalizes that cessation.
This action has no effect on the Company's principal listing on the NASDAQ
Capital Market.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 30, 2009.